Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Odevixibat
Therapeutic Area : Genetic Disease
Study Phase : Approved
Recipient : Albireo Pharma
Deal Size : Undisclosed
Deal Type : Partnership
Details : The agreement with Genpharm advances Albireo’s global strategy for the commercialization of Bylvay in a key region following European and U.S. regulatory approvals of the use of Bylvay in patients with PFIC based on the PEDFIC study.
Brand Name : Bylvay
Molecule Type : Small molecule
Upfront Cash : Undisclosed
August 18, 2021
Lead Product(s) : Odevixibat
Therapeutic Area : Genetic Disease
Highest Development Status : Approved
Recipient : Albireo Pharma
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Autologous CD34+ cell enriched HSPC
Therapeutic Area : Genetic Disease
Study Phase : Approved
Recipient : Orchard Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Under terms of the agreements, GenPharm and GEN will be responsible for all activities related to identifying patients, driving disease awareness, and ensuring market access for Libmeldy in their respective territories.
Brand Name : Libmeldy
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
January 19, 2021
Lead Product(s) : Autologous CD34+ cell enriched HSPC
Therapeutic Area : Genetic Disease
Highest Development Status : Approved
Recipient : Orchard Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
LOOKING FOR A SUPPLIER?